Company: OCEA
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-011080
Chunk: 44

Company: Ocean Biomedical, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1A
Chunk 44
---
writers were involved in the sales and the certificates (or book entry notations) representing the securities sold and issued contain
legends restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration.

Issuances of Capital Stock

In connection with the
amendment and restatement of the Ayrton Convertible Note Financing, dated July 15, 2024, in January 2025, we issued to the Investor
3,844,466 shares of our common stock. This transaction was affected without registration under the Securities Act in reliance on the
exemption from registration provided under Section 4(a)(2) of the Securities Act.

In January 2025, we issued to
the Investor 1,332,806 shares of our common stock in connection with the exercise of the warrant B. This transaction was affected without
registration under the Securities Act in reliance on the exemption from registration provided under Section 4(a)(2) of the Securities
Act.

During the first quarter of 2025,
we issued to the Investor 125,964,905 shares of our common stock in connection with conversion notices received in accordance with the
terms of the 2024 Convertible Notes. These transaction were affected without registration under the Securities Act in reliance on the
exemption from registration provided under Section 4(a)(2) of the Securities Act.

During
the period of April 2025 and the first week of May 2025, we issued to the Investor an additional 66,354,338 shares of our common stock
in connection with conversion notices received in accordance with the terms of the 2024 Convertible Notes. These transactions were affected
without registration under the Securities Act in reliance on the exemption from registration provided under Section 4(a)(2) of the Securities
Act.

Issuer Purchases of Equity
Securities

We did not purchase any shares
of our common stock during the quarter ended March 31, 2025.

51

Item 6. Exhibits.

    Exhibit Number
     
    Description
  
    2.1
     
    Agreement and Plan of Merger, dated as of August 31, 2022 by and between Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc.), AHAC Merger Sub Inc., Aesther Healthcare Sponsor, LLC, Dr. Chirinjeev Kathuria and Ocean Biomedical, Inc. (n/k/a Ocean Biomedical Holdings, Inc.) (inc